KDR and prostate cancer: However, combination of VEGFR2 tyrosine kinase inhibitors may potentiate the effects of docetaxel in prostate cancer cells (Monteverde et al, 2011) and available preclinical data suggest that BIBF 1120 in combination with chemotherapy may enhance the activity of cytotoxic agents (Ulahannan and Brahmer, 2011).